Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

Neurology

Volumn 60, Issue 1, 2003, Pages 37-43

  Polman, C ^a   Kappos, L ^d   White, R ^d   Dahlke, F ^b   Beckmann, K ^b   Pozzilli, C ^d   Thompson, A ^c   Petkau, J ^d   Miller, D ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BAYER PHARMA AG   (Germany)

^c National Hospital   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT PLANNING;

EID: 0037435532     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.1.37     Document Type: Article

References (26)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. European Study Group in Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
5. Antonelli G. In vivo development of antibody to interferons: an update to 1996. J Interferon Cytokine Res 1997;1(suppl):39-46.
6. IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
7. Rudick RA, Simonian NA, Alani JA, et al. Incidence and significance of neutralising antibodies in interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
8. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
9. SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496-1504.
10. Paszner B, Petkau J, Oger J. Neutralising antibodies to interferon beta in the treatment of multiple sclerosis: cause for concern? CNS Drugs 1999;11:225-243
11. Li DKB, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group, and SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-1513.
12. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-beta in patients treated with recombinant interferon-beta-1a from mammalian cells. Cytokine Cell Mol Ther 1997;3:27-32.
13. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN beta-1a. J Interferon Cytokine Res 1998;18:345-350.
14. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFNB-1b: the use of an assay for neutralizing antibody. Neurology 1996;47:865-866.
15. Pungor E, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralising antibodies to interferon beta-1b. J Interferon Cytokine Res 1998;18:1025-1030.
16. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024.
17. Polman CH, Dahlke F, Thompson AJ, et al. Interferon beta-1b in secondary progressive multiple sclerosis - outline of the clinical trial. Mult Scler 1995;1:S51-S54.
18. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European Multicenter Trial on IFNbeta-1b in Secondary-Progressive MS. Neurology 2001;57:1969-1975.
19. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
20. Liang KY, Zeger SL. Regression analysis for correlated data. Ann Rev Public Health 1993;14:43-68.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
22. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-1839.
23. D'yachkova Y, Petkau J, White R. Longitudinal analyses for magnetic resonance imaging outcomes in multiple sclerosis clinical trials. J Biopharm Stat 1997;7:501-531.
24. IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995;45:1277-1285.
25. Oger J, Vorobeychick G, Paty DW. In Betaseron-treated MS patients, in vitro immune function can be a predictor of neutralizing antibody development. Neurology 1997;48:A80. Abstract.
26. Rice GPA, Paszner B, Oger J, Lesaux RN, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279.